Needham & Company LLC reissued their hold rating on shares of Medtronic (NYSE:MDT – Free Report) in a research report report published on Friday, Benzinga reports.
A number of other research firms have also commented on MDT. Oppenheimer upped their price target on Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a research report on Wednesday, August 21st. Robert W. Baird upped their price target on Medtronic from $82.00 to $90.00 and gave the company a “neutral” rating in a research report on Wednesday, August 21st. Royal Bank of Canada raised Medtronic from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $98.00 to $105.00 in a research report on Thursday, October 10th. Wells Fargo & Company upped their price target on Medtronic from $105.00 to $106.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Finally, Daiwa America raised Medtronic to a “strong-buy” rating in a research report on Friday, August 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Medtronic has a consensus rating of “Hold” and a consensus price target of $95.36.
Read Our Latest Research Report on MDT
Medtronic Trading Down 0.4 %
Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.03. The company had revenue of $7.97 billion during the quarter, compared to analysts’ expectations of $7.90 billion. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. Medtronic’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.20 EPS. As a group, sell-side analysts anticipate that Medtronic will post 5.44 earnings per share for the current year.
Medtronic Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, October 11th. Investors of record on Friday, September 27th were paid a $0.70 dividend. The ex-dividend date was Friday, September 27th. This represents a $2.80 annualized dividend and a dividend yield of 3.09%. Medtronic’s payout ratio is currently 94.59%.
Institutional Trading of Medtronic
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fortitude Family Office LLC purchased a new stake in shares of Medtronic in the 3rd quarter worth approximately $27,000. Highline Wealth Partners LLC purchased a new stake in Medtronic during the 3rd quarter valued at $27,000. Lynx Investment Advisory purchased a new stake in Medtronic during the 2nd quarter valued at $28,000. Tributary Capital Management LLC purchased a new stake in Medtronic during the 1st quarter valued at $33,000. Finally, Gleason Group Inc. purchased a new stake in Medtronic during the 2nd quarter valued at $42,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Further Reading
- Five stocks we like better than Medtronic
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Differences Between Momentum Investing and Long Term Investing
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Stock Market Sectors: What Are They and How Many Are There?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.